Source of Funding: none MP07-10 THE FREQUENCY OF DRUGGABLE TARGETS IN LOCALIZED PROSTATE CANCER: INITIAL ANALYSIS FROM THE DECIPHER GRID Elai Davicioni*, san diego, CA; Nicholas Erho, Lucia Lam, Mandeep Takhar, Hussam Al-Deen Ashab, Anders Olson, Michael Dillon, kasra yousefi, zaid haddad, Penelope Wood, mohammed alshalalfa, vancouver, Canada INTRODUCTION AND OBJECTIVES: Prostate cancers patient management has been enhanced with several commercially available genomic prognostic tests such as the Decipherâ prostate cancer classifier. These tests are useful for making local therapy treatment decision-making. In addition to being the most validated predictor of metastasis in prostate cancer, Decipher is also a genome-wide assay that measures the expression of many druggable targets METHODS: Decipher GRID (Genomic Resource Information Database), was queried to assess the expression patterns of 15 genes from 5 biological pathways (Table 1) in 2,111 radical prostatectomy patients from prospective Decipher commercial cases. The frequency of high (or low) expression of each gene was ascertained using the me- dian absolute deviation (MAD) metric. Patients with gene expression above the median + 1.5*1.48*MAD were annotated as high expression and patients with gene expression below the median e 1.5*1.48*MAD were annotated as low expression RESULTS: Median age at RP was 67 years and median pre- operative PSA was 6.2 ng/mL. Extraprostatic extension, seminal vesicle invasion and lymph node involvement were present in 55%, 21% and 3% of patient tumors. Gleason score ¼8 tumors were found in 42% of patients tested. The frequency of patients in the cohort with low or high expression of the targets is reported in the table below. CONCLUSIONS: Since every patient who has received the Decipher test also has a genome-wide expression profile, the Decipher GRID will allow researchers to evaluate on a systematic population- level the expression of genes that may be targeted with existing ther- apies. Proliferation and GF receptors genes generally have a right skewed distribution while AR signalling genes that have left skewed profile. Using a conservative cut-off for outlier expression, the fre- quencies of most druggable genes are <10% in this localized disease population. Such information may be useful for selection of optimal systemic therapy and inclusion into clinical trials of novel targeted agents. Source of Funding: GenomeDx Biosciences MP07-11 INTRADUCTAL CARCINOMA OF THE PROSTATE IS AN INDEPENDENT FACTOR FOR DISTANT METASTASES AT INITIAL RECURRENCE: AN INSIGHT TO TREATMENT PLANNING. Jennifer Sirois, Vincent Q. Trinh*, Babak K. Mansoori, Andr ee-Anne Grosset, Roula Albadine, Mathieu Latour, Fred Saad, Dominique Trudel, Montreal, Canada INTRODUCTION AND OBJECTIVES: Intraductal carcinoma of the prostate (IDC-P) is present in 13-48% of radical prostatectomy (RP) specimens. Though associated with higher risk of clinical recurrence, the type of recurrence has not yet been distinguished. The aim of this study is to investigate IDC-P in RP specimens of patients who presented with either local or distant clinical recurrence of prostate cancer. METHODS: Our cohort included men enrolled in our institu- tional or PROCURE tissue bank treated with first-line RP between 1993 and 2011 who subsequently experienced initial recurrence through either local or distant events. Only specimens with >75% of blocks available were considered. Cases were blindly reviewed to identify IDC- P and to update Gleason score according to current guidelines. Local recurrence is defined as limited to the peri-prostatic area or to regional lymph nodes, whereas distant recurrence developed beyond regional lymph nodes. Statistical analyses were performed in SPSS v.20 with Pearson chi-square, Student t-test or Fisher exact test for univariate tests, and multinomial logistic regression for multivariate tests. RESULTS: Histopathological material was retrieved from 50 men with clinical recurrence: 39 men with distant and 11 with local re- currences. Univariate tests determined no significant differences be- tween groups for age, Gleason score, lymphovascular invasion, extraprostatic extension, seminal vesicle invasion, surgical margin status nor regional lymph node status (Table 1). IDC-P was identified in 89.7% of (35/39) distant cases and 45.5% (5/11) of local cases. After correction for all previous factors, multivariate analyses identified an odds-ratio of 14.0 (95%CI [1.94-101], p¼0.009) for distant metastases at initial recurrence when IDC-P was present on RP (Table 2). CONCLUSIONS: In our cohort, IDC-P was an independent risk factor for distant metastases on initial recurrence, suggesting systemic adjuvant therapy could be considered ealier in treatment planning. e80 THE JOURNAL OF UROLOGY â Vol. 195, No. 4S, Supplement, Friday, May 6, 2016